10X Genomics, a Bay Area startup that’s building out extensive next-generation sequencing services, just closed out a $55 million Series C round – meant largely to fuel sales and marketing growth.
Investors include Fidelity Management, Softback, JS Capital Management, Venrock, Foresite Capital, and Paladin Capital.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
The company’s product suite uses whole genome sequencing, single gene expression analysis and careful exome analysis to unveil new structural variants and haplotypes – thus painting a broader picture of human health. It sells instruments, reagents and software to make sense of a huge swath of sequenced genetic data.
Notably, last month 10X Genomics signed a comarketing agreement with Illumina to promote its Linked-Read sequencing products.
